目的 探讨卡培他滨联合放射治疗老年中晚期食管癌的效果.方法 选取2013年3月~2015年7月我院收治的76例老年中晚期食管癌患者作为研究对象,按照随机数字表法分为参照组(38例)与观察组(38例).参照组患者给予放射治疗,观察组患者给予卡培他滨联合放射治疗,两组的疗程均为6 周.比较两组患者的临床治疗效果、不良反应发生情况及治疗后3年内的生存情况.结果 观察组患者的总有效率(73.68%) 高于参照组 (50.00%),差异有统计学意义(P<0.05);观察组患者的1年生存率(84.21%)高于参照组(60.53%),差异有统计学意义(P<0.05);两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05).结论 卡培他滨联合放射治疗老年中晚期食管癌的效果显著,可有效缓解患者的病情,提高患者的生存率,且该治疗方式的安全性较高,轻微不良反应不影响患者病情的缓解,值得在临床治疗上广泛应用.
Objective To investigate the effect of Capecitabine combined with radiotherapy in the treatment of elderly patients with advanced esophageal cancer. Methods A total of 76 elderly patients with advanced esophageal cancer admitted to our hospital from March 2013 to July 2015 were selected as the study subjects, they were divided into control group (38 cases) and observation group (38 cases) according to random number table method. The control group was treated with radiotherapy, while the observation group was treated with Capecitabine combined with radiotherapy, the course of treatment in both groups was 6 weeks. The clinical efficacy, adverse reactions and survival within 3 years after treatment were compared between the two groups. Results The total effective rate of the observation group (73.68%) was higher than that of the control group (50.00%), the difference was statistically significant (P<0.05). The 1-year survival rate of the patients in the observation group (84.21%) was higher than that in the control group (60.53%), the difference was statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Capecitabine combined with radiotherapy in the treatment of elderly patients with advanced esophageal cancer has a remarkable effect. It can effectively alleviate the patient's condition and improve the survival rate of patients. Moreover, the treatment method has a high safety, and minor adverse reactions do not affect the remission of patients'condition. It is worthy of wide application in clinical treatment.